Financial statements are reported in DKK and shown here converted to USD at today's exchange rate.
NVO — Novo Nordisk A/S
$41.63
+$0.98 (+2.41%)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Market Cap
$183.52B
Forward P/E
1.8x
52-Week Range
N/A
NVO Price History
Revenue vs. Net Income
$45.6B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$4.3B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
41.2%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.6x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
29.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-0.3%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
